Cubicin Resistance Should Be Closely Monitored In Bacteremia Patients
Labeling regarding use of Cubist's anti-infective Cubicin in Staphylococcus aureus patients should include a recommendation for close monitoring for development of resistance, members of FDA's Anti-Infective Drugs Advisory Committee said March 6
You may also be interested in...
Cubist will increase its Cubicin (daptomycin) sales force by one third in the first quarter, bringing the total to 100 reps, CEO Michael Bonney said
FDA will continue work on defining an indication for primary bacteremia due to Staph aureus (PBSA) after the agency found support for the claim from the Anti-Infective Drugs Advisory Committee
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011